Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 182

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 182
---
 was hired to support ZILRETTA. This transition impacted first quarter sales as ZILRETTA is a promotionally sensitive product. The decrease was partially offset by a 1% increase in net selling price per unit set in January 2025. The increase in net selling price per unit is related to a 4% increase in gross selling price per unit, partially offset by higher sales-related allowances.

Net product sales of iovera° increased 2% in the three months ended March 31, 2025 versus 2024 primarily due to a 1% increase in Smart Tip net selling price per unit.

Bupivacaine liposome injectable suspension revenue increased 3% and its related royalties increased 3% in the three months ended March 31, 2025 versus 2024, respectively, primarily due to the sales mix of vial sizes and the timing of orders placed for veterinary use.

The following tables provide a summary of activity with respect to our sales-related allowances and accruals related to EXPAREL and ZILRETTA for the three months ended March 31, 2025 and 2024 (in thousands):

March 31, 2025ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2024$1,600 $1,308 $4,875 $4,863 $1,707 $14,353 Provision225 3,384 5,223 35,003 1,094 44,929 Payments(150)(3,276)(6,080)(36,149)(1,403)(47,058)Balance at March 31, 2025$1,675 $1,416 $4,018 $3,717 $1,398 $12,224 

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 42

March 31, 2024ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2023$1,868 $1,308 $3,697 $5,870 $1,175 $13,918 Provision76 3,057 4,771 25,800 636 34